Meeting
2022 ASCO Annual Meeting
FOLFOXIRI + bevacizumab versus FOLFOX/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases (CRLM) and right-sided and/or RAS/BRAFV600E-mutated primary tumor: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group.
Presenter
Cornelis J. A. Punt, MD, PhD
University Medical Center Utrecht
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT02162563
Citation
J Clin Oncol 40, 2022 (suppl 17; abstr LBA3506)
DOI
10.1200/JCO.2022.40.17_suppl.LBA3506
Abstract #
LBA3506
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2019 ASCO Annual Meeting
Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 baseline circulating tumor cells (bCTCs).
Speaker: Javier Sastre, MD, PhD
Speaker: Panel Discussion
Videos & Slides
2013 ASCO Annual Meeting
FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group.
Speaker: Alfredo Falcone, MD
Videos & Slides
2024 ASCO Annual Meeting
Impact of colorectal liver metastases (CRLM) in patients with metastatic colorectal cancer (mCRC) receiving trifluridine/tipiracil (FTD/TPI) with or without bevacizumab (BEV) in the phase 3 SUNLIGHT trial.
Speaker: Josep Tabernero, MD, PhD, FASCO